We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
Cap. Flow
-$193M
Cap. Flow %
-4.53%
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$52.4M
2
CI icon
Cigna
CI
+$48.2M
3
UTHR icon
United Therapeutics
UTHR
+$38.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$29.4M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$28.9M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$105M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$93.6M
3
THC icon
Tenet Healthcare
THC
+$81.8M
4
BSX icon
Boston Scientific
BSX
+$39.8M
5
CYTK icon
Cytokinetics
CYTK
+$35.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANRO icon
101
Alto Neuroscience
ANRO
$1.38B
$1M 0.02%
250,000
– –
LYEL icon
102
Lyell Immunopharma
LYEL
$356M
$840K 0.02%
51,727
– –
KZR
103
DELISTED
Kezar Life Sciences
KZR
$752K 0.02%
192,700
– –
XERS icon
104
Xeris Biopharma Holdings
XERS
$1.55B
$655K 0.02%
80,420
– –
PASG icon
105
Passage Bio
PASG
$14.5M
$474K 0.01%
59,046
-243,719
-80% -$1.7M
DHAI
106
DELISTED
DIH Holdings US
DHAI
$358K 0.01%
76,600
– –
VTGN icon
107
CALL
VistaGen Therapeutics
VTGN
$11.2M
$160K ﹤0.01%
+45,200
New +$135K
ABCL icon
108
AbCellera Biologics
ABCL
$3.68B
– –
-3,344,568
Closed -$11.5M
AGIO icon
109
Agios Pharmaceuticals
AGIO
$1.99B
– –
-557,900
Closed -$18.6M
CGON icon
110
CALL
CG Oncology
CGON
$6.59B
– –
-150,000
Closed -$3.9M
CMMB
111
Chemomab Therapeutics
CMMB
$19.9M
– –
-235,248
Closed -$1.09M
CPRX
112
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-416,900
Closed -$9.05M
CYTK icon
113
Cytokinetics
CYTK
$10B
– –
-1,077,000
Closed -$35.6M
ENGN icon
114
enGene Therapeutics
ENGN
$122M
– –
-677,977
Closed -$2.47M
INMB icon
115
PUT
INmune Bio
INMB
$64.7M
– –
-50,000
Closed -$116K
ITOS
116
DELISTED
iTeos Therapeutics
ITOS
– –
-700,000
Closed -$6.98M
THC icon
117
Tenet Healthcare
THC
$21.5B
– –
-465,000
Closed -$81.8M
THRD
118
DELISTED
Third Harmonic Bio
THRD
– –
-5,779,071
Closed -$31.4M
TSBX
119
DELISTED
Turnstone Biologics
TSBX
– –
-3,099,265
Closed -$1.11M
TYRA icon
120
Tyra Biosciences
TYRA
$1.49B
– –
-804,603
Closed -$7.7M
UNH icon
121
CALL
UnitedHealth
UNH
$353B
– –
-50,000
Closed -$15.6M
UNH icon
122
UnitedHealth
UNH
$353B
– –
-336,300
Closed -$105M
VRTX icon
123
Vertex Pharmaceuticals
VRTX
$137B
– –
-210,287
Closed -$93.6M
ZLAB icon
124
Zai Lab
ZLAB
$2.93B
– –
-231,000
Closed -$8.08M
LSB
125
DELISTED
LakeShore Biopharma
LSB
– –
-54,799
Closed -$55.9K
1 2 3 4
5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2025 Portfolio in Review

As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.

  • OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
  • OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
  • OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
  • OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
  • OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
  • OrbiMed opened 24 new positions and closed 18 in Q3 2025.
  • OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.